PeerJ · 2026
Serum ferritin as a potential biomarker for distinguishing advanced-stage colorectal cancer: a retrospective cohort study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cao Chuanpei, Tang Fan, Zhu Zhihua, Wang Feng, Li Jinfeng
Аннотация
BACKGROUND: Colorectal cancer (CRC) stage plays a major role in treatment decisions and prognosis. This study investigates whether Serum Ferritin can improve CRC staging and compares its performance to standard markers like carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA).
METHODS: We analyzed data from 419 CRC patients at Jiujiang College Affiliated Hospital, dividing them into early-stage (I-II, 245 patients) and late-stage (III-IV, 174 patients) groups. Logistic regression and receiver operating characteristic (ROC) curves were used to assess the usefulness of serum ferritin compared with traditional markers.
RESULTS: Serum Ferritin was significantly higher in late-stage CRC (P < 0.001). ROC analysis showed Serum Ferritin had a numerically higher area under the curve (AUC) (0.795) compared to CA 19-9 (0.745) and CEA (0.744) at distinguishing between early and advanced stages. The combined model yielded an AUC of 0.890.
CONCLUSION: Serum Ferritin could be a useful addition to CRC staging, showing a numerically higher AUC than current markers. Adding it to clinical practice may help refine stage assessment and guide treatment decisions. This study supports its potential as a supplementary tool for stage assessment in CRC management.
METHODS: We analyzed data from 419 CRC patients at Jiujiang College Affiliated Hospital, dividing them into early-stage (I-II, 245 patients) and late-stage (III-IV, 174 patients) groups. Logistic regression and receiver operating characteristic (ROC) curves were used to assess the usefulness of serum ferritin compared with traditional markers.
RESULTS: Serum Ferritin was significantly higher in late-stage CRC (P < 0.001). ROC analysis showed Serum Ferritin had a numerically higher area under the curve (AUC) (0.795) compared to CA 19-9 (0.745) and CEA (0.744) at distinguishing between early and advanced stages. The combined model yielded an AUC of 0.890.
CONCLUSION: Serum Ferritin could be a useful addition to CRC staging, showing a numerically higher AUC than current markers. Adding it to clinical practice may help refine stage assessment and guide treatment decisions. This study supports its potential as a supplementary tool for stage assessment in CRC management.